Zobrazeno 1 - 10
of 96
pro vyhledávání: '"John D. Chester"'
Autor:
Emily A. Bates, James A. Davies, Jana Váňová, Davor Nestić, Valerie S. Meniel, Sarah Koushyar, Tabitha G. Cunliffe, Rosie M. Mundy, Elise Moses, Hanni K. Uusi-Kerttula, Alexander T. Baker, David K. Cole, Dragomira Majhen, Pierre J. Rizkallah, Toby Phesse, John D. Chester, Alan L. Parker
Publikováno v:
Molecular Therapy: Oncolytics, Vol 25, Iss , Pp 43-56 (2022)
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre-existing immunity will be beneficial for future clinical translation. We generated a low-seroprevale
Externí odkaz:
https://doaj.org/article/e338981455f0434ea7eb7c74250e7338
Autor:
James A. Davies, Gareth Marlow, Hanni K. Uusi-Kerttula, Gillian Seaton, Luke Piggott, Luned M. Badder, Richard W. E. Clarkson, John D. Chester, Alan L. Parker
Publikováno v:
Viruses, Vol 13, Iss 5, p 864 (2021)
We previously developed a refined, tumor-selective adenovirus, Ad5NULL-A20, harboring tropism ablating mutations in each major capsid protein, to ablate all native means of infection. We incorporated a 20-mer peptide (A20) in the fiber knob for selec
Externí odkaz:
https://doaj.org/article/0de1c5c44a1c4abe94c824c0b12e335e
Autor:
Alan L. Parker, John D. Chester, Richard G. Vile, Emma Hudson, Louise Hanna, Rachel Jones, Pierre J. Rizkallah, Alexander T. Baker, Angela Bradshaw, Kevin G. Shim, Laura Evgin, Phonphimon Wongthida, Jill M. Thompson, James A. Davies, Hanni Uusi-Kerttula
Supplemental Figure I. Homology modelling of the Ad5NULL-A20 complex; Supplement II. Biodistribution study: Heat-map images of luminescence intensity ex vivo; Supplement II. Biodistribution study: Immunohistochemistry on formalin-fixed, paraffinembed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5118354084c71ab24d42dcfe9445c27e
https://doi.org/10.1158/1078-0432.22474649.v1
https://doi.org/10.1158/1078-0432.22474649.v1
Autor:
Alan L. Parker, John D. Chester, Richard G. Vile, Emma Hudson, Louise Hanna, Rachel Jones, Pierre J. Rizkallah, Alexander T. Baker, Angela Bradshaw, Kevin G. Shim, Laura Evgin, Phonphimon Wongthida, Jill M. Thompson, James A. Davies, Hanni Uusi-Kerttula
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors for the manipulability and tolerance of transgenes. Poor tumor selectivity, off-target sequestration, and immune inactivation hamper clinical efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe214a92fa9bbdbcf9b2d158c1ff494
https://doi.org/10.1158/1078-0432.c.6528854
https://doi.org/10.1158/1078-0432.c.6528854
Autor:
John D. Chester, Saoirse Dolly, Ricard Mesia, Nadia Harbeck, Salvatore Grisanti, Gino M Dettorre, M. C. Carmona-Garcia, O. Mirallas, Nikolaos Diamantis, Alexia Bertuzzi, Rossella Bertulli, J. Tabernero, Uma Mukherjee, Andrea Patriarca, Christopher C T Sng, Alessandra Gennari, Valeria Tovazzi, Cristina Cruz, Federica Biello, Mark Bower, Raquel Liñan, P. Seeva, A. Roque, David J. Pinato, Elia Seguí, Nadia Saoudi-Gonzalez, Carlo Tondini, A. Maconi, Lorenza Rimassa, Armando Santoro, Michela Libertini, Enriqueta Felip, Alvin J.X. Lee, Thomas Newsom-Davis, Diego Ottaviani, Bruno Vincenzi, A. Loizidou, Neha Chopra, Juan Aguilar-Company, Alberto Zambelli, Vittoria Fotia, Amanda Jackson, Charlotte Moss, Daniele Generali, Ailsa Sita-Lumsden, Joan Brunet, Andrea Marrari, Ramon Salazar, Beth Russell, Gianpiero Rizzo
Publikováno v:
Clinical Cancer Research. 27:S01-03
We sought to determine parameters of the acute phase response, a feature of innate immunity activated by infectious noxae and cancer, deranged by Covid-19 and establish oncological indices’ prognostic potential for patients with concomitant cancer
Autor:
Jason F. Lester, Gareth Griffiths, John D. Chester, Tony Elliott, Robert Jones, Simon J. Crabb, Chao Huang, Robert Huddart, Tracie-Ann Madden, Satinder Jagdev, Angela C. Casbard, A. Birtle, L. Evans
Publikováno v:
BJU International. 126:292-299
Objectives To assess the efficacy and tolerability of the dual EGFR/VEGFR inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first line treatment of patients with advanced urolthelial cancer (UC) who were unsuitable for cis
Autor:
Gianpiero Rizzo, Eudald Felip, Annalisa Guida, Alessio Cortellini, Francesca Mazzoni, Rachel Sharkey, Alice Baggi, Emeline Colomba, Sabrina Rossi, Salvatore Grisanti, Federica Zoratto, David J. Pinato, Daniela Ferrante, Claudia Andrea Cruz, Giampero Porzio, Lorenzo Chiudinelli, Alessandra Gennari, Alexia Bertuzzi, Gianluca Gaidano, Joan Brunet, Johann Colomba, Alessia Dalla Pria, Nadia Harbeck, Raffaele Giusti, Alberto Zambelli, Angela Loizidou, Clara Martinez-Vila, Daniele Generali, Matteo Lambertini, Isabel Ruiz-Camps, Paola Queirolo, Michela Libertini, Ana Sanchez de Torre, Ailsa Sita-Lumsden, Laura Fox, Federica Biello, Javier Marco-Hernández, Nikolaos Diamantis, Elia Seguí, Lorenza Rimassa, Nadia Saoudi-Gonzalez, Ariadna Roqué Lloveras, Armando Santoro, John D. Chester, Mieke Van Hemelrijck, Carlo Tondini, Marco Krengli, Saoirse Dolly, Raquel Liñan, Elisa Roldán, Charlotte Moss, Diego Ottaviani, Fanny Pommeret, Uma Mukherjee, Andrea Patriarca, Aleix Prat, Joanne Evans, Rossana Berardi, Meera Patel, Mark Bower, Marco Tagliamento, Paolo Pedrazzoli, Juan Aguilar-Company, Lorenza Scotti, Bruno Vincenzi, Irina Earnshaw, M Carmen Carmona-García, Anna Pous, Thomas Newsom-Davis, Riccardo Bruna, Krishnie Srikandarajah, Rossella Bertulli, Josep Tabernero, Vittoria Fotia, Alessandro Parisi, Anna Sureda, Ramon Salazar, Beth Russell, Michela Franchi, Roxana Reyes
Publikováno v:
JAMA Oncol
JAMA Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JAMA Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
IMPORTANCE Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE To test whether severity and mortality from COVID-19 among patients with cance
Autor:
Emily A. Bates, James A. Davies, Jana Váňová, Davor Nestić, Valerie S. Meniel, Sarah Koushyar, Tabitha G. Cunliffe, Rosie M. Mundy, Elise Moses, Hanni K. Uusi-Kerttula, Alexander T. Baker, David K. Cole, Dragomira Majhen, Pierre J. Rizkallah, Toby Phesse, John D. Chester, Alan L. Parker
Publikováno v:
Molecular Therapy-Oncolytics
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre- existing immunity will be beneficial for future clinical translation. We generated a low- seropreva
Autor:
Luke Piggott, Hanni Uusi-Kerttula, James A. Davies, Richard W. E. Clarkson, John D. Chester, Luned Badder, Gillian Seaton, Alan L. Parker, Gareth Marlow
Publikováno v:
Viruses, Vol 13, Iss 864, p 864 (2021)
Viruses
Volume 13
Issue 5
Viruses
Volume 13
Issue 5
We previously developed a refined, tumor-selective adenovirus, Ad5NULL-A20, harboring tropism ablating mutations in each major capsid protein, to ablate all native means of infection. We incorporated a 20-mer peptide (A20) in the fiber knob for selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb4e51da051c4f23d5ffb681ab5fc2f8
Autor:
Emma Hudson, Richard G. Vile, Rachel Jones, Louise Hanna, Angela C. Bradshaw, Alexander T. Baker, John D. Chester, Pierre J. Rizkallah, Laura Evgin, Phonphimon Wongthida, James A. Davies, Kevin G. Shim, Jill Thompson, Alan L. Parker, Hanni Uusi-Kerttula
Publikováno v:
Clinical Cancer Research. 24:4215-4224
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors for the manipulability and tolerance of transgenes. Poor tumor selectivity, off-target sequestration, and immune inactivation hamper clinical efficac